Clofarabine. Mfr: Genzyme


Indications and Reactions:

Role Indications Reactions
Primary
Acute Lymphocytic Leukaemia 58.2%
Acute Myeloid Leukaemia 26.1%
Myeloid Leukaemia 3.7%
Bone Marrow Conditioning Regimen 2.1%
Chronic Myeloid Leukaemia 1.9%
Acute Myeloid Leukaemia Recurrent 1.4%
Drug Use For Unknown Indication 1.4%
Non-hodgkin's Lymphoma 1.0%
T-cell Lymphoma 1.0%
Myelodysplastic Syndrome 0.8%
Accidental Exposure 0.4%
Non-hodgkin's Lymphoma Recurrent 0.4%
T-cell Type Acute Leukaemia 0.4%
Acute Leukaemia 0.2%
Adult T-cell Lymphoma/leukaemia 0.2%
Diffuse Large B-cell Lymphoma 0.2%
Disease Recurrence 0.2%
Lymphoma 0.2%
White Blood Cell Count Decreased 16.9%
Vomiting 11.7%
Respiratory Failure 9.1%
Pancytopenia 5.2%
Pyrexia 5.2%
Toxic Epidermal Necrolysis 5.2%
Venoocclusive Disease 5.2%
Weight Decreased 5.2%
Sepsis 3.9%
Subcutaneous Abscess 3.9%
Tachycardia 3.9%
White Blood Cell Count Abnormal 3.9%
Febrile Neutropenia 2.6%
Neutropenic Infection 2.6%
Pulmonary Congestion 2.6%
Renal Failure 2.6%
Septic Shock 2.6%
Skin Warm 2.6%
Stem Cell Transplant 2.6%
Systemic Mycosis 2.6%
Secondary
Acute Lymphocytic Leukaemia 91.5%
Acute Myeloid Leukaemia 6.5%
Myeloid Leukaemia 1.0%
Acute Myeloid Leukaemia Recurrent 0.4%
Bone Marrow Conditioning Regimen 0.3%
Non-hodgkin's Lymphoma Recurrent 0.2%
White Blood Cell Count Decreased 28.9%
Weight Decreased 19.3%
Streptococcal Infection 8.4%
Varicella 8.4%
Viral Skin Infection 7.2%
White Blood Cell Count Abnormal 6.0%
Pancytopenia 3.6%
Venoocclusive Liver Disease 2.4%
Vomiting 2.4%
Febrile Neutropenia 1.2%
Insomnia 1.2%
Lipase Increased 1.2%
Oral Candidiasis 1.2%
Renal Disorder 1.2%
Respiratory Disorder 1.2%
Respiratory Failure 1.2%
Respiratory Rate Increased 1.2%
Skin Warm 1.2%
Streptococcal Bacteraemia 1.2%
Tachycardia 1.2%

Drug Data